Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $6.5714.

NMRA has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Needham & Company LLC dropped their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings cut shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Finally, Royal Bank Of Canada decreased their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th.

Insider Activity

In related news, insider Daljit Singh Aurora sold 21,055 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $1.60, for a total transaction of $33,688.00. Following the transaction, the insider owned 48,750 shares of the company’s stock, valued at approximately $78,000. This trade represents a 30.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 453,833 shares of company stock valued at $701,219. 26.94% of the stock is currently owned by corporate insiders.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Siren L.L.C. boosted its position in Neumora Therapeutics by 35.1% during the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after buying an additional 2,209,039 shares during the period. BlackRock Inc. bought a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at about $13,246,000. Perceptive Advisors LLC purchased a new stake in Neumora Therapeutics during the 1st quarter valued at about $9,953,000. ICONIQ Capital LLC bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $4,350,000. Finally, Johnson & Johnson bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $3,144,057. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Stock Down 2.7%

Shares of NASDAQ:NMRA opened at $0.73 on Friday. The firm has a market capitalization of $137.17 million, a PE ratio of -0.59 and a beta of 2.71. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50. Neumora Therapeutics has a 52-week low of $0.71 and a 52-week high of $3.65. The firm has a fifty day moving average of $1.45 and a 200 day moving average of $1.86.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. As a group, research analysts anticipate that Neumora Therapeutics will post -0.84 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and neuropsychiatric disorders. The company combines neuroscience research with data science and computational tools to identify disease mechanisms, discover potential drug targets and support the development of precision medicines for conditions affecting the brain.

Neumora’s pipeline includes navacaprant, an investigational selective kappa opioid receptor antagonist being developed for major depressive disorder.